Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06402058
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-13
First Post:
2024-05-02
Brief Title:
A Study Comparing DMSB01 and Rejuran for Temporary Crows Feet Lines Improvement
Sponsor:
Samyang Biopharmaceuticals Corporation
Organization:
Samyang Biopharmaceuticals Corporation
Study Overview
Official Title:
A Randomized Subject and Evaluator Blinded Matched Pairs Pilot Study to Evaluate the Safety and Efficacy of DMSB01 According to the Number of Injections in Subjects With Crows Feet Lines Compared to Control Device
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this Pilot Study is to verify the safety and efficacy of DMSB01 in the temporary improvement of Crows Feet Lines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None